Saleem Aman, MD
Internal Medicine · Franklin, WINPI 1487691556
Payments from drug & device makers
Across 76 payments — averaging $46.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$931
- AbbVie$487
- Boehringer Ingelheim$481
- Novo Nordisk$436
- Lilly USA, LLC$394
- Pfizer$164
- plus $614 from 13 others
What the payments were for
- Food & beverage$3,497100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $931 |
| AbbVie(2 entities) | 8 | $487 |
| Boehringer Ingelheim | 5 | $481 |
| Novo Nordisk | 9 | $436 |
| Lilly USA, LLC | 11 | $394 |
| Pfizer | 5 | $164 |
| Johnson & Johnson | 3 | $132 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Ardelyx, Inc. | 7 | $111 |
| Exact Sciences | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Abbott | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $19 |
| GSK | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,508 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 165 | $190,433 |
| JardianceEmpagliflozin | 107 | $155,384 |
| EliquisApixaban | 63 | $73,561 |
| TrulicityDulaglutide | 45 | $56,010 |
| XareltoRivaroxaban | 45 | $52,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $51,130 |
| LinzessLinaclotide | 56 | $50,716 |
| FarxigaDapagliflozin Propanediol | 28 | $38,656 |
| OzempicSemaglutide | 34 | $37,481 |
| MyrbetriqMirabegron | 27 | $23,501 |
| TradjentaLinagliptin | 18 | $15,388 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,545 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $4,287 |
| Atorvastatin Calcium | 437 | $3,373 |
| Levothyroxine Sodium | 379 | $3,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $394 | $246,443210 claims |
| Boehringer IngelheimJardiance, Tradjenta | $481 | $170,772125 claims |
| PfizerEliquis | $164 | $73,56163 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $63,67586 claims |
| Johnson & JohnsonXarelto | $132 | $52,03945 claims |
| AbbVieLinzess, Synthroid | $487 | $51,87774 claims |
| AstraZenecaFarxiga | $931 | $38,65628 claims |
| Novo NordiskOzempic | $436 | $37,48134 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $23,50127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Franklin
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.